APP 0205
Alternative Names: APP-0205Latest Information Update: 30 Apr 2021
At a glance
- Originator Aphios Corporation
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Influenza virus infections
Most Recent Events
- 01 Apr 2021 APP 0205 is available for licensing as of 01 Apr 2021. https://aphios.com/products/therapeutic-products-pipeline/infectious-disease/anti-influenza-therapeutics/
- 01 Apr 2021 Early research in Influenza virus infections in USA (unspecified route) before April 2021 (Aphios Corporation website, April 2021)